ZYME
Zymeworks Inc

2,640
Mkt Cap
$1.7B
Volume
1.53M
52W High
$26.19
52W Low
$9.03
PE Ratio
-26.69
ZYME Fundamentals
Price
$23.82
Prev Close
$22.60
Open
$23.00
50D MA
$17.87
Beta
0.87
Avg. Volume
869,862.13
EPS (Annual)
-$1.62
P/B
5.35
Rev/Employee
$266,797.20
Loading...
Loading...
News
all
press releases
Zymeworks (NYSE:ZYME) Sees Unusually-High Trading Volume After Analyst Upgrade
Zymeworks (NYSE:ZYME) Sees Strong Trading Volume After Analyst Upgrade...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Zymeworks (NYSE:ZYME) Shares Gap Up - Should You Buy?
Zymeworks (NYSE:ZYME) Shares Gap Up - Here's What Happened...
MarketBeat·2d ago
News Placeholder
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
Zacks·2d ago
News Placeholder
Zymeworks Shifts To Royalty-Driven Model From Licensed Drugs, Approves $125M Buyback Plan
The company now expects future partnerships and collaborations to play a significant role in funding ongoing research and development investments, thereby reducing its reliance on internal capital.
Stocktwits·2d ago
News Placeholder
Zymeworks Appoints Scott Platshon Acting Chief Investment Officer
(RTTNews) - Zymeworks Inc. (ZYME), a Canadian biotechnology company, Tuesday said that it has appointed Scott Platshon as Acting Chief Investment Officer...
Nasdaq News: Markets·3d ago
News Placeholder
Zymeworks Inc. (NYSE:ZYME) Given Consensus Rating of "Moderate Buy" by Brokerages
Zymeworks Inc. (NYSE:ZYME - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are covering the company, Marketbeat Ratings reports. One...
MarketBeat·3d ago
News Placeholder
Zymeworks Rallies 30% On Positive Phase 3 Results For Ziihera In First-Line GEA
(RTTNews) - Zymeworks Inc. (ZYME) surged 30.02% to $24.08, up $5.56, after announcing positive topline results from its Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab-hrii) with...
Nasdaq News: Markets·3d ago
News Placeholder
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.read more...
Benzinga·3d ago
News Placeholder
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
read more...
Benzinga·3d ago
News Placeholder
Stock Market Today: S&P 500, Nasdaq Open Lower to Start Week, Continuing Last Week's Red Row
This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here.Happy Monday. This is TheStreet's Stock...
TheStreet.com·3d ago

Latest ZYME News

View

Advertisement|Remove ads.

Advertisement|Remove ads.